into action
"Clinical trials to date indicate that motexafin gadolinium is a novel oncology drug with activity in a variety of cancers."
Minesh Mehta, M.D. University of WisconsinWe are leveraging our small-molecule drug development expertise to build a pipeline in oncology and immune-mediated diseases based on novel targets, pathways and mechanisms. We have several products in development, each derived from structure-based research. Motexafin gadolinium (MGd) is a Phase 3 drug candidate that has shown promising activity in brain metastases from lung cancer and other oncology indications. Multiple histone deacetylase (HDAC) inhibitors, both broad-spectrum (PCI-24781) – meaning they target all forms of HDAC enzymes – and isoform-selective (HDAC8) are being developed for solid tumors and lymphomas. Our pan HDAC inhibitor is now in a multicenter Phase 1 trial for solid tumors and a Phase 2 trial for hematologic malignancies. Our Factor VIIa inhibitor, PCI-27483, possesses a novel mechanism of action that targets both the tumor and thrombotic disease that often occurs in patients with cancer, and is now in a Phase 1 trial. Finally, our lead Btk inhibitor, PCI-32765, shows promising activity in animal models of lymphoma and rheumatoid arthritis and will soon enter clinical trials in lymphoma patients.